A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly ...

Add Yahoo as a preferred source to see more of our stories on Google. Can a monthly injection be the key to curbing addiction? These experts say yes. OAKLAND, Calif. — Dr. Andrew Herring has a clear ...

Please provide your email address to receive an email when new articles are posted on . Brixadi is the first long-acting buprenorphine injectable that is available in weekly and monthly doses.

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Add Yahoo as a preferred source to see more of our stories on Google. EYEWITNESS NEWS (WBRE/WYOU) — The U.S. Food and Drug Administration (FDA) approved a Buprenorphine treatment option for opioid ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In a clinical trial supported by the National Institutes of Health (NIH), a research team found that administering weekly injectable extended-release buprenorphine for treatment of opioid use disorder ...

BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...

Pregnant patients with opioid use disorder (OUD) who received subcutaneous extended-release buprenorphine had higher rates of abstinence from illegal opioids than those who received the sublingual ...

The US Food and Drug Administration (FDA) has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder (OUD). The ...